Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Technical Perspectives on ITUS Corp., Cenveo, Acacia Research, and Priceline

NEW YORK, Dec. 08, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on ITUS, CVO, ACTG, and PCLN which is a click away at http://www.wallstequities.com/registration. This morning, WallStEquties.com reexplores the Business Services space, which covers a broad range of industries involved in the provision of a range of business services, including those related to providing professional advice and consulting services; facilities management; information and communication services; and arts, entertainment, and recreation services. Lined up for assessment this morning are: ITUS Corp. (NASDAQ: ITUS), Cenveo Inc. (NASDAQ: CVO), Acacia Research Corp. (NASDAQ: ACTG), and The Priceline Group Inc. (NASDAQ: PCLN). Wall St. Equities explores the latest technical developments on today's equity selection at: http://www.wallstequities.com/registration

ITUS Corp.

Shares in Los Angeles, California-based ITUS Corp. rose 3.19%, ending Thursday's trading session at $2.59. The stock recorded a trading volume of 180,518 shares. The Company's shares have surged 292.31% over the last three months. The stock is trading 40.06% above its 200-day moving average. Moreover, shares of ITUS Corp., which funds, develops, acquires, and licenses emerging technologies in the areas of biotechnology, have a Relative Strength Index (RSI) of 48.71.  

On December 06th, 2017, ITUS Corp. announced that its abstract titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," was accepted for presentation at the 2nd annual American Society of Clinical Oncology-Society for Immunotherapy of Cancer Clinical Immuno-oncology Symposium, which will be held from January 25th, 2018 to January 27th, 2018 in San Francisco, California. Myeloid-derived suppressor cells, or MDSCs, are a key group of white blood cells that form the foundation for the Company's liquid biopsy technology. Complimentary subscription to our free research report on ITUS at: http://www.wallstequities.com/registration/?symbol=ITUS

Cenveo

Stamford, Connecticut headquartered Cenveo Inc.'s stock climbed 1.85%, closing the day at $1.10. A total volume of 1.34 million shares was traded, which was above their three months average volume of 534,500 shares. The Company's shares are trading 34.24% below their 50-day moving average. Additionally, shares of Cenveo, which provides print related products in the US and internationally, have an RSI of 44.41. Access the free research report on CVO now by signing up at: http://www.wallstequities.com/registration/?symbol=CVO

Acacia Research

On Thursday, shares in Newport Beach, California headquartered Acacia Research Corp. recorded a trading volume of 150,210 shares. The stock ended the day 1.22% higher at $4.15. The Company's shares have advanced 10.67% in the previous three months, and are trading below their 50-day moving average by 2.19%. Furthermore, shares of Acacia Research, which through its subsidiaries, invests in, develops, licenses, and enforces patented technologies in the US, have an RSI of 46.03. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ACTG at: http://www.wallstequities.com/registration/?symbol=ACTG

Priceline Group

Norwalk, Connecticut headquartered The Priceline Group Inc.'s stock gained 0.03%, finishing yesterday's session at $1,719.62. A total volume of 503,624 shares was traded, which was above their three months average volume of 477,360 shares. The Company's shares have advanced 4.49% in the last one month and 17.30% on an YTD basis. The stock is trading below its 50-day moving average by 6.05%. Additionally, shares of Priceline, which provides online travel and restaurant reservation, and related services, have an RSI of 35.28. 

On November 28th, 2017, OpenTable, part of Priceline Group, announced that, in the spirit of the holiday season, Company diners will have the opportunity to donate their dining points to No Kid Hungry®, a campaign of the US anti-hunger, non-profit organization, Share Our Strength. Points donations made from November 28th, 2017, through December 11th, 2017 will benefit the campaign, which provides nutritious meals to children struggling with hunger nationwide.

On December 07th, 2017, research firm MKM Partners downgraded the Company's stock rating from 'Buy' to 'Neutral'. Aspiring Member, please take a moment to register below for your free research report on PCLN at: http://www.wallstequities.com/registration/?symbol=PCLN

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 

View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-itus-corp-cenveo-acacia-research-and-priceline-300568907.html

SOURCE Wall St. Equities

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.